Licorice root (Glycyrrhiza glabra) has a long history in traditional medicine and has been studied for its antiviral and immunomodulatory properties. The active component, glycyrrhizin, has demonstrated in vitro antiviral activity against a variety of viruses, including Epstein-Barr Virus (EBV). Laboratory studies have shown that glycyrrhizin can inhibit the replication of EBV in cell cultures, likely by interfering with viral gene expression and replication processes. Additionally, licorice root extracts may help modulate immune responses, which can be beneficial in managing chronic or reactivated EBV infections.

Despite these promising laboratory findings, there is limited clinical evidence to support the effectiveness of licorice root in treating or managing EBV infections in humans. Most of the available evidence comes from cell or animal studies, and few human trials have been conducted specifically for EBV. As a result, while the scientific rationale exists and preclinical studies are encouraging, robust clinical trials are lacking. This means that licorice root's use for EBV is scientifically plausible but not yet well validated for clinical application. Care should also be taken with licorice root, as excessive use can cause side effects such as hypertension and electrolyte imbalances.

In summary, licorice root is used to support EBV based on its observed antiviral activity in laboratory studies, but high-quality human evidence is currently insufficient, justifying a moderate evidence rating.